PTGIR prostaglandin I2 receptor
ENSG00000160013 · protein coding · Open Targets profile
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
gnomAD loss of function constraint: o/e 0.9083600044250488 (upper bound 1.3796000480651855). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 126 registry trials, updated in the last three years, of the most advanced drugs against PTGIR (treprostinil, iloprost, epoprostenol, selexipag, esuberaprost, ralinepag, treprostinil diolamine), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Pär I JohanssonCopenhagen University Hospital, Rigshospitalet · 3 of 3 trials Phase 2+
- Wade BentonCivibio Pharma, Inc. · 3 of 3 trials Phase 2+
- Aaron B WaxmanBrigham and Women's Hospital, Pulmonary Vascular Disease Program · 2 of 2 trials Phase 2+
- Aline FreyActelion · 2 of 2 trials Phase 2+
- James SeiboldScleroderma Research Consultants LLC · 2 of 2 trials Phase 2+
- Nicholas S HillTufts Medical Center · 2 of 2 trials Phase 2+
- Ralph PreissActelion · 2 of 2 trials Phase 2+
- York E MillerNorthwestern University · 1 of 2 trials Phase 2+
- Alexander RothmanUniversity of Sheffield · 1 of 1 trials Phase 2+
- Ali AtayaUniversity of Florida · 1 of 1 trials Phase 2+
- Amadeo MarcosUniversity of Pittsburgh Medical Center · 1 of 1 trials Phase 2+
- Anders PernerCopenhagen University Hospital, Intensive care Unit 4131 · 1 of 1 trials Phase 2+
- André DenaultMontreal Heart Institute · 1 of 1 trials Phase 2+
- Arek J WiktorUniversity of Colorado, Denver · 1 of 1 trials Phase 2+
- Caio FernandesInstituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo · 1 of 1 trials Phase 2+
Registry trials of treprostinil, iloprost, epoprostenol, selexipag, esuberaprost, ralinepag, treprostinil diolamine updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 67 of 108 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 18 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
67 trials of drugs against PTGIR were stopped early; 7 give no reason
Terminated, withdrawn and suspended interventional trials of treprostinil, iloprost, epoprostenol, selexipag, esuberaprost, ralinepag, treprostinil diolamine, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 67.
- terminated · 2026-07-06 · United Therapeutics · Ralinepag“Sponsor decision”
- terminated · 2026-05-27 · United Therapeutics · Inhaled treprostinil solution“Sponsor's decision”
- terminated · 2025-03-30 · Actelion · matched by the registry's drug synonyms“The Sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate.”
- terminated · 2025-02-04 · Actelion · Inhaled Iloprost (5 μg)“Terminated due to slow enrollment”
- terminated · 2024-10-15 · Duke University · Inhaled Iloprost“Project was completed”
- terminated · 2024-06-21 · Actelion · Selexipag“The study did not demonstrate efficacy on the primary endpoint, PVR vs. placebo at wk 20 at a planned interim analysis.”
- terminated · 2024-06-18 · United Therapeutics · treprostinil diethanolamine“The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled TDE-DU-201 study did not meet its primary efficacy objective.”
- withdrawn · 2024-05-17 · National Cancer Institute (NCI) · Iloprost“Agent is not available”
- terminated · 2024-05-08 · Actelion · Selexipag“The sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate”
- terminated · 2024-04-02 · Duke University · Iloprost and nitric oxide administration“slow enrollment”
- terminated · 2024-03-05 · United Therapeutics · matched by the registry's drug synonyms“Sponsor Decision”
- terminated · 2024-01-03 · United Therapeutics · treprostinil“Study closed due to limited availability of eligible subjects and competition by for enrollment by other studies”
- terminated · 2024-01-03 · United Therapeutics · treprostinil sodium“Due to availability of eligible subjects at center and enrollment competition with other studies.”
- withdrawn · 2023-12-19 · United Therapeutics · treprostinil sodiumNo reason given
- terminated · 2023-12-12 · University Hospital, Grenoble · Treprostinil iontophoresis“recruitment difficulties”
- terminated · 2023-11-24 · United Therapeutics · Inhaled treprostinil solution“Sponsor's decision”
- terminated · 2023-09-22 · Insmed Incorporated · Treprostinil Palmitil“Low enrolment”
- withdrawn · 2023-06-06 · Mardi Gomberg -Maitland MD, MSc · Treprostinil Diolamine“never opened to enrollment because it was never funded”
- terminated · 2023-02-01 · Jewish General Hospital · matched by the registry's drug synonyms“Safety considerations”
- terminated · 2022-12-02 · United Therapeutics · Inhaled Treprostinil“Inhaled treprostinil became commercially available in the US following its approval for PH-ILD”
- terminated · 2022-04-12 · Inova Health Care Services · Inhaled Treprostinil“Unable to enroll”
- terminated · 2022-03-31 · Stanford University · Treprostinil“Interim futility analysis”
- terminated · 2021-09-13 · Liquidia Technologies, Inc. · Inhaled dry powder treprostinil (LIQ861)“COVID”
- terminated · 2020-11-10 · United Therapeutics · Oral treprostinil“Terminated by sponsor”
- terminated · 2020-10-22 · United Therapeutics · Oral treprostinil“Terminated by Sponsor”
Paediatric incentives and obligations for PTGIR's drugs
For treprostinil, iloprost, epoprostenol, selexipag, esuberaprost, ralinepag, treprostinil diolamine: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · PTGIR is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002432-PIP02-20-M01 (ralinepag, Treatment of pulmonary arterial hypertension): PM: decision on the application for modification of an agreed PIP, 19 Jul 2024; EMEA-003182-PIP01-22-M01 (treprostinil sodium, Treatment of pulmonary arterial hypertension): PM: decision on the application for modification of an agreed PIP, 1 Dec 2023; EMEA-000997-PIP01-10-M07 (selexipag, Treatment of pulmonary arterial hypertension): PM: decision on the application for modification of an agreed PIP, 25 Oct 2023; compliance positive 19 Jan 2024; EMEA-000207-PIP01-08-M08 (treprostinil, Treatment of pulmonary arterial hypertension): PM: decision on the application for modification of an agreed PIP, 14 Jun 2023; +2 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/25/3066 positive 20 Jun 2025: Treatment of systemic sclerosis; EU/3/22/2588 positive 16 Mar 2022: Treatment of idiopathic pulmonary fibrosis; EU/3/04/197 positive 14 Apr 2004: Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension; EU/3/18/2130 positive 11 Jan 2019: Treatment of pulmonary arterial hypertension; +3 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Uptravi: authorised since 12 May 2016; Ventavis: authorised since 15 Sept 2003; Trepulmix: authorised since 3 Apr 2020, orphan medicine; Orepaxam: application withdrawn, orphan medicine; +2 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of treprostinil, iloprost, epoprostenol, selexipag, esuberaprost, ralinepag, treprostinil diolamineRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 39 interventional studies of treprostinil, iloprost, epoprostenol, selexipag, esuberaprost, ralinepag, treprostinil diolamine include patients under 18; 6 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 9 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.